Does Adjuvant Therapy in Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Improve Survival? A Systematic Review and Meta-Analysis Using Trial Sequential Analysis

辅助治疗能否提高胰腺浸润性导管内乳头状黏液性肿瘤患者的生存率?一项基于试验序贯分析的系统评价和荟萃分析

阅读:3

Abstract

OBJECTIVE: This meta-analysis aims to evaluate the efficacy of adjuvant therapy (ADJ) in patients with resected invasive IPMNs, compared with follow-up (FUP). METHODS: A random effects meta-analysis was performed. Meta-regression analysis was used to clarify heterogeneity. The trial sequential analysis was used to test Type I and Type II errors, defining the required information size (RIS). The primary endpoint was OS, and the secondary endpoint was DFS. RESULTS: The accrued sample size (AIS) was 2422 patients for OS and 493 patients for DFS. OS and DFS in the ADJ arm were similar to the FUP arm (HR 1.21; 95% CI 0.81-1.79, p = 0.349 and HR 0.98; 95% CI 0.64-1.51, p = 0.936). The RIS were 2422 for OS and 254 for DFS, allowing the exclusion of Type II errors. For the primary endpoint, heterogeneity was high (I(2) = 98%). Meta-regression analysis showed that, although considering two groups equal for confounding covariates, OS in the ADJ and FUP arms remains similar. A subgroup analysis showed that node-positive patients have improved OS after adjuvant therapy administration (HR 1.86; 95% CI 1.39; 2.47, p < 0.001). CONCLUSION: Adjuvant therapy should not be administered indiscriminately to all patients. Node-positive invasive IPMN seems to have an improved OS. TRIAL REGISTRATION: PROSPERO 2024 CRD42024561326.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。